Raymond James Financial Inc. Takes Position in Enovis Co. (NYSE:ENOV)

Raymond James Financial Inc. acquired a new stake in Enovis Co. (NYSE:ENOV) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 373,911 shares of the company’s stock, valued at approximately $16,407,000. Raymond James Financial Inc. owned 0.66% of Enovis as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UMB Bank n.a. raised its position in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares in the last quarter. FMR LLC raised its position in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after acquiring an additional 484 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Enovis during the 3rd quarter worth about $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new stake in shares of Enovis during the 4th quarter worth about $228,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC cut their target price on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Trading Up 5.9 %

ENOV opened at $39.23 on Tuesday. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -17.91 and a beta of 2.05. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79. The business’s 50 day moving average is $43.21 and its two-hundred day moving average is $43.67. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, research analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.